The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.
 
Fred R. Hirsch
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech; HTG Molecular Diagnostics; Lilly; Merck; Pfizer; Roche; Ventana Medical Systems
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Lilly/ImClone (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
 
Mary Weber Redman
Consulting or Advisory Role - Bristol-Myers Squibb; Millennium; Takeda
 
Roy S. Herbst
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; NovaRX; pfizer
Consulting or Advisory Role - Biothera; DiaTech Oncology; Endocyte; Kolltan Pharmaceuticals; N-of-One
Research Funding - Genentech/Roche
 
Edward S. Kim
Honoraria - AstraZeneca; Celgene; Lilly
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Lilly; Myriad Genetics
Research Funding - Celgene; Lilly
 
Thomas John Semrad
Consulting or Advisory Role - Amgen; Celgene; Eisai; Genentech; Genzyme (I); Onyx
Research Funding - Astex Pharmaceuticals (Inst); Eisai (Inst); Genentech (Inst); Millennium (Inst); Morphotek (Inst); Novartis (Inst)
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - AstraZeneca; Genoptix; Heat Biologics; Pfizer
Speakers' Bureau - Genentech; Novartis
 
Gregory A. Masters
No Relationships to Disclose
 
Kurt R. Oettel
No Relationships to Disclose
 
Perry Guaglianone
No Relationships to Disclose
 
Christopher M. Reynolds
No Relationships to Disclose
 
Anand B. Karnad
No Relationships to Disclose
 
Susanne M. Arnold
No Relationships to Disclose
 
Marileila Varella-Garcia
Research Funding - Abbott Molecular (Inst)
Patents, Royalties, Other Intellectual Property - Molecular diagnostics of NTRK rearrangements (Inst)
 
James Moon
No Relationships to Disclose
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Apton Biosystems; AstraZeneca; MolecularMD
Research Funding - Boehringer Ingelheim
Travel, Accommodations, Expenses - Guardant Health
 
Charles David Blanke
Travel, Accommodations, Expenses - Novartis
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Synta (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; Roche; Synta
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer